These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 26626080)

  • 1. Recombinant Adeno Associated Viral (AAV) vector type 9 delivery of Ex1-Q138-mutant huntingtin in the rat striatum as a short-time model for in vivo studies in drug discovery.
    Ceccarelli I; Fiengo P; Remelli R; Miragliotta V; Rossini L; Biotti I; Cappelli A; Petricca L; La Rosa S; Caricasole A; Pollio G; Scali C
    Neurobiol Dis; 2016 Feb; 86():41-51. PubMed ID: 26626080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease.
    Franich NR; Fitzsimons HL; Fong DM; Klugmann M; During MJ; Young D
    Mol Ther; 2008 May; 16(5):947-56. PubMed ID: 18388917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of a rat model of Huntington's disease based on targeted expression of mutant huntingtin in the forebrain using adeno-associated viral vectors.
    Gabery S; Sajjad MU; Hult S; Soylu R; Kirik D; Petersén Å
    Eur J Neurosci; 2012 Sep; 36(6):2789-800. PubMed ID: 22731249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length.
    de Almeida LP; Ross CA; Zala D; Aebischer P; Déglon N
    J Neurosci; 2002 May; 22(9):3473-83. PubMed ID: 11978824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AAV-mediated delivery of the transcription factor XBP1s into the striatum reduces mutant Huntingtin aggregation in a mouse model of Huntington's disease.
    Zuleta A; Vidal RL; Armentano D; Parsons G; Hetz C
    Biochem Biophys Res Commun; 2012 Apr; 420(3):558-63. PubMed ID: 22445760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Exogenous NUB1 Expression in the Striatum of HDQ175/Q7 Mice.
    Vodicka P; Chase K; Iuliano M; Valentine DT; Sapp E; Lu B; Kegel-Gleason KB; Sena-Esteves M; Aronin N; DiFiglia M
    J Huntingtons Dis; 2016 Jun; 5(2):163-74. PubMed ID: 27314618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inducing huntingtin inclusion formation in primary neuronal cell culture and in vivo by high-capacity adenoviral vectors expressing truncated and full-length huntingtin with polyglutamine expansion.
    Huang B; Schiefer J; Sass C; Kosinski CM; Kochanek S
    J Gene Med; 2008 Mar; 10(3):269-79. PubMed ID: 18067195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington's disease.
    Miniarikova J; Zimmer V; Martier R; Brouwers CC; Pythoud C; Richetin K; Rey M; Lubelski J; Evers MM; van Deventer SJ; Petry H; Déglon N; Konstantinova P
    Gene Ther; 2017 Oct; 24(10):630-639. PubMed ID: 28771234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenovirus vector-based in vitro neuronal cell model for Huntington's disease with human disease-like differential aggregation and degeneration.
    Dong X; Zong S; Witting A; Lindenberg KS; Kochanek S; Huang B
    J Gene Med; 2012 Jul; 14(7):468-81. PubMed ID: 22700462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progressive and selective striatal degeneration in primary neuronal cultures using lentiviral vector coding for a mutant huntingtin fragment.
    Zala D; Benchoua A; Brouillet E; Perrin V; Gaillard MC; Zurn AD; Aebischer P; Déglon N
    Neurobiol Dis; 2005 Dec; 20(3):785-98. PubMed ID: 16006135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice.
    Rodriguez-Lebron E; Denovan-Wright EM; Nash K; Lewin AS; Mandel RJ
    Mol Ther; 2005 Oct; 12(4):618-33. PubMed ID: 16019264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic manipulations of mutant huntingtin in mice: new insights into Huntington's disease pathogenesis.
    Lee CY; Cantle JP; Yang XW
    FEBS J; 2013 Sep; 280(18):4382-94. PubMed ID: 23829302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of nuclear mutant huntingtin inclusion formation in neurons and glia is cell-type-specific.
    Jansen AH; van Hal M; Op den Kelder IC; Meier RT; de Ruiter AA; Schut MH; Smith DL; Grit C; Brouwer N; Kamphuis W; Boddeke HW; den Dunnen WF; van Roon WM; Bates GP; Hol EM; Reits EA
    Glia; 2017 Jan; 65(1):50-61. PubMed ID: 27615381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significantly differential diffusion of neuropathological aggregates in the brain of transgenic mice carrying N-terminal mutant huntingtin fused with green fluorescent protein.
    Cheng PH; Li CL; Her LS; Chang YF; Chan AW; Chen CM; Yang SH
    Brain Struct Funct; 2013 Jan; 218(1):283-94. PubMed ID: 22422149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early and reversible neuropathology induced by tetracycline-regulated lentiviral overexpression of mutant huntingtin in rat striatum.
    Régulier E; Trottier Y; Perrin V; Aebischer P; Déglon N
    Hum Mol Genet; 2003 Nov; 12(21):2827-36. PubMed ID: 12952868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A role of mitochondrial complex II defects in genetic models of Huntington's disease expressing N-terminal fragments of mutant huntingtin.
    Damiano M; Diguet E; Malgorn C; D'Aurelio M; Galvan L; Petit F; Benhaim L; Guillermier M; Houitte D; Dufour N; Hantraye P; Canals JM; Alberch J; Delzescaux T; Déglon N; Beal MF; Brouillet E
    Hum Mol Genet; 2013 Oct; 22(19):3869-82. PubMed ID: 23720495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adeno-Associated Viral Vector Serotype DJ-Mediated Overexpression of N171-82Q-Mutant Huntingtin in the Striatum of Juvenile Mice Is a New Model for Huntington's Disease.
    Jang M; Lee SE; Cho IH
    Front Cell Neurosci; 2018; 12():157. PubMed ID: 29946240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cleavage at the 586 amino acid caspase-6 site in mutant huntingtin influences caspase-6 activation in vivo.
    Graham RK; Deng Y; Carroll J; Vaid K; Cowan C; Pouladi MA; Metzler M; Bissada N; Wang L; Faull RL; Gray M; Yang XW; Raymond LA; Hayden MR
    J Neurosci; 2010 Nov; 30(45):15019-29. PubMed ID: 21068307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrajugular vein delivery of AAV9-RNAi prevents neuropathological changes and weight loss in Huntington's disease mice.
    Dufour BD; Smith CA; Clark RL; Walker TR; McBride JL
    Mol Ther; 2014 Apr; 22(4):797-810. PubMed ID: 24390280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained effects of nonallele-specific Huntingtin silencing.
    Drouet V; Perrin V; Hassig R; Dufour N; Auregan G; Alves S; Bonvento G; Brouillet E; Luthi-Carter R; Hantraye P; Déglon N
    Ann Neurol; 2009 Mar; 65(3):276-85. PubMed ID: 19334076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.